As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
New collection: Advances in CAR-T immunotherapy
Chimeric antigen receptor (CAR) T cells therapies, as a novel modality in cancer immunotherapy, provide a quantum leap in the treatment of cancer. BMC Cancer and BMC Biotechnology together present the latest collection of articles on the advances in CAR-T immunotherapy covering the entire range of advances from lab to clinic. Click on highlight to read the the full collection of articles.
COVID-19 Announcement
Trending BMC Cancer Articles
Click here to view which Articles have been shared most in the last 6 months!
Articles
-
-
Thyroid cancer in Ecuador
-
Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
-
Head & neck acinar cell carcinoma: a population-based study using the seer registry
-
A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report
-
Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression
-
Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma
-
Time trends in municipal distribution patterns of cancer mortality in Spain
-
M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide
-
Li-Fraumeni syndrome with simultaneous osteosarcoma and liver cancer: Increased expression of a CD44 variant isoform after chemotherapy
Featured review: Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico
Gallbladder cancer is a rare malignancy of the biliary tract with a poor prognosis, frequently presenting at an advanced stage. While rare in the United States overall, gallbladder cancer has an elevated incidence in geographically distinct locations of the globe including Chile, North India, Korea, Japan and the state of New Mexico in the United States. Rama R. Gullapalli, Associate Editor for BMC Cancer provides this review.
Featured video: Microparticles, breast cancer's secret weapon?
Your browser needs to have JavaScript enabled to view this video
Featured review: A stepwise approach to constructing systematic reviews
Systematic reviews, with or without meta-analysis, play an important role today in synthesizing cancer research and are frequently used to guide decision-making. With a focus on cancer, first author, Prof Kelley, provides a practical, stepwise approach for systematically reviewing the literature and publishing the results.
Featured article: Are cancer patients better off if they participate in clinical trials?
How do physicians and nurses perceive the benefits of clinical trial participation compared with standard care? Is it justified to claim that clinical trial participation improves outcomes for cancer patients? Zandra Nielsen et al. present their latest findings of a mixed-methods study in Scandinavia.
Aims and scope
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.
Journal Sections
- Cell and molecular biology
- Biomarkers
- Epidemiology, prevention and public health
- Experimental therapeutics and drug development
- Genetics, genomics and epigenetics
- Infection, immunity and cancer vaccines
- Medical and radiation oncology
- Surgical oncology, cancer imaging and interventional therapeutics
- Systems biology, post-genomic analysis and emerging technologies
- Supportive therapy, cancer burden and survivorship
Editor
Linda Gummlich, BMC Series, London, UK
Assistant Editors
Catherine Rice, Senior Assistant Editor, BMC Series, London
William Spenceley Jones, Assistant Editor, BMC Series, London
Consulting Editors
Yanis Boumber, Fox Chase Cancer Center, USA
Ken Herrmann, Universitätsklinikum Essen, Germany
Alan Lefor, Jichi Medical University, Japan
Christophe Nicot, Kansas University Medical Center, USA
Stephen Povoski, The Ohio State University, USA
Dirk Vordermark, Martin Luther University Halle-Wittenberg, Germany
Cross-journal thematic series: Precision Oncology
We are proud to finally present the publications from our cross-journal thematic series, Precision Oncology. This collection focuses on how precision oncology has shaped advances in the impact of non-coding RNAs in epigenetics and cancer, immunotherapy and tumor biology. Also of note are the technological developments for preclinical routines and the clinical significance of various therapies in breast, esophageal, liver, lung, ovarian cancers, among other types.
Read our highly accessed articles
Editorial: Nobel Prize Cancer Immunotherapy!
Follow Nobel Prize laureates James P. Allison's and Tasuku Honjo's footsteps and experience the genesis of a new field of cancer therapy. BMC Cancer Editorial Board Member Dr. Sheng Guo from Pittsburgh University takes us on an exciting journey of discovery...
BMC Series Blog
Follow
2019 Journal Metrics
-
Citation Impact
3.15 - 2-year Impact Factor
3.432 - 5-year Impact Factor
1.021 - Source Normalized Impact per Paper (SNIP)
1.186 - SCImago Journal Rank (SJR)Usage
4,151,734 downloads
Social Media Impact
3364 mentions
